Proteinuria following sirolimus conversion is associated with deterioration of kidney function in liver transplant recipients

Transplantation

Volumn 93, Issue 10, 2012, Pages 1006-1012

  Wadei, Hani M ^a   Zaky, Ziad S ^a   Keaveny, Andrew P ^a   Rosser, Barry ^a   Jones, Melanie ^a   Mai, Martin L ^a   Bulatao, Ilynn ^a   Gonwa, Thomas A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Calcineurin inhibitor nephrotoxicity; Kidney function; Liver transplantation; Proteinuria; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; DETERIORATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; URINARY EXCRETION;

AGED; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 84861101145     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824bbd01     Document Type: Article

References (35)

1. Gonwa TA, McBride MA, Mai ML, et al. Kidney transplantation after previous liver transplantation: Analysis of the Organ Procurement Transplant Network Database. Transplantation 2011; 92: 31.
2. Srinivas TR, Stephany BR, Budev M, et al. An emerging population: Kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. Clin J Am Soc Nephrol 2010; 5: 1881.
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
4. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934.
5. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62: 364.
6. Kamar N, Guilbeau-Frugier C, Servais A, et al. Kidney histology and function in liver transplant patients. Nephrol Dialysis Transplant 2011; 26: 2355.
7. Sehgal SN. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
8. Fairbanks KD, Eustace JA, Fine D, et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079.
9. Harper SJ, Gelson W, Harper IG, et al. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: A single-center experience. Transplantation 2011; 91: 128.
10. Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694.
11. Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: A prospective, randomized, single-center trial. Transplantation 2007; 83: 1389.
12. Campbell MS, Rai J, Kozin E, et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007; 21: 377.
13. DuBay D, Smith RJ, Qiu KG, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transplant 2008; 14: 651.
14. Asrani SK, Leise MD, West CP, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta-analysis. Hepatology 2010; 52: 1360.
15. Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transplant 2009; 15: S1.
16. Diekmann F, Gutierrez-Dalmau A, Lopez S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol Dial Transplant 2007; 22: 2316.
17. Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368.
18. Aliabadi AZ, Pohanka E, Seebacher G, et al. Development of proteinuria after switch to sirolimus-based immunosuppression in longterm cardiac transplant patients. Am J Transplant 2008; 8: 854.
19. Morard I, Dumortier J, Spahr L, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13: 658.
20. Thomusch O, Tittelbach-Helmrich D, Seifert G, et al. Late-onset proteinuria after antithymocyte globulin induction and de novo sirolimus monotherapy in kidney transplant recipients. Transplantation 2011; 92: E62.
21. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126.
22. Straathof-Galema L,Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006; 6: 429.
23. Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: Evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 2011; 91: 997.
24. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 2088.
25. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5: 2441.
26. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517.
27. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326.
28. Padiyar A, Bodziak KA, Hricik DE, et al. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. Am J Transplant 2010; 10: 310.
29. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 1066.
30. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: Prevalence and predictive factors. J Hepatol 1996; 25: 64.
31. Shields PL, Tang H, Neuberger JM, et al. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 1999; 68: 530.
32. Samuelson A, Lee M, Kamal A, et al. Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score. Digest Dis Sci 2010; 55: 2089.
33. Paramesh AS, Roayaie S, Doan Y, et al. Post-liver transplant acute renal failure: Factors predicting development of end-stage renal disease. Clin Transplant 2004; 18: 94.
34. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741.
35. LaMattina JC, Foley DP, Mezrich JD, et al. Chronic kidney disease stage progression in liver transplant recipients. Clin J Am Soc Nephrol 2011; 6: 1851.